FIELD: medicine, pathology. SUBSTANCE: the method deals with patients suffering α-galactosidase A (gal A) deficiency. Patient is introduced with a human cell genetically modified for superexpression and secretion of human α-gal A. The method, also, includes polypeptisis-coding DNA molecule which contains α-gal A, purification method and therapeutic composition. EFFECT: higher efficiency of therapy. 12 cl, 13 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF α-GALACTOSIDASE A INSUFFICIENCY | 2000 |
|
RU2248213C2 |
| DNA CONSTRICT FOR HOMOLOGICAL RECOMBINATION (VARIANTS), TRANSCRIPTION UNIT (VARIANT), METHOD FOR CELL HOMOLOGICAL RECOMBINATION AND METHOD FOR ALTERATION OF TARGET GENE EXPRESSION IN CELL | 1995 |
|
RU2267533C2 |
| HYBRID MATRIX IMPLANTS AND EXPLANTS | 1996 |
|
RU2201765C2 |
| MODIFYING EXPRESSION OF FSHβ GENE USING HOMOLOGOUS RECOMBINATION | 1999 |
|
RU2229309C2 |
| PROTEIN PRODUCTION | 2005 |
|
RU2429243C2 |
| METHOD FOR PRODUCING HUMAN IMMUNE INTERFERON | 1988 |
|
RU2107728C1 |
| ISOLATED DNA MOLECULE ENCODING HUMAN ERYTHROPOIETIN (VARIANTS), EXPRESSING PLASMID OR VIRAL DNA-VECTOR, GLYCOPROTEIN ERYTHROPOIETIN (VARIANTS) AND METHOD FOR ITS PREPARING, PHARMACEUTICAL COMPOSITION (VARIANTS), MAMMALIAN CELL LINE (VARIANTS) | 1985 |
|
RU2261276C2 |
| PRODUCTION OF GLYCOPROTEINS WITH MODIFIED FUCOSYLATION | 2008 |
|
RU2479629C2 |
| PRODUCTION OF BIOLOGICALLY ACTIVE PROTEINS | 2007 |
|
RU2441911C2 |
| METHODS AND COMPOSITIONS FOR TREATING FABRY DISEASE | 2020 |
|
RU2822369C2 |
